In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
CAS:PRO's Price-to-Net-Current-Asset-Value is ranked worse than 65.8% of 614
companies
in the Drug Manufacturers industry
Industry Median: 5.305
vs CAS:PRO: 8.24
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM (CAS:PRO) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM Net Current Asset Value Related Terms
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM Net Current Asset Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM Net Current Asset Value Chart
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM Annual Data
CAS:PRO vs ZTS, UTHR, VTRS: Net Current Asset Value Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM Price-to-Net-Current-Asset-Value vs Drug Manufacturers Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of MAD163.72 mean?
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM (CAS:PRO) has a Net Current Asset Value of MAD163.72 as of Dec. 2025. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM and its competitors. This is 2871% above median its historical median of 5.51. Over the past decade, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's Net Current Asset Value has ranged from 2.44 to 10.25. According to the industry distribution chart, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM ranks #404 out of 614 companies in the Drug Manufacturers industry, placing it in the top 65.8%.
Is PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's Net Current Asset Value too high?
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's current Net Current Asset Value of MAD163.72 is 2871% above median its 10-year median of 5.51. Over the past 10 years, this metric has ranged from a low of 2.44 to a high of 10.25. Based on the distribution chart, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM ranks #404 out of 614 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM has a GF Score™ of 84/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's Net Current Asset Value compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM ranks #404 out of 614 companies for Net Current Asset Value. This places PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM in the lower half of its industry. The industry median Net Current Asset Value is 5.31. Historically, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's own Net Current Asset Value has ranged from 2.44 to 10.25 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Drug Manufacturers company?
The median Net Current Asset Value among Drug Manufacturers companies is 5.31, based on 614 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM and its competitors. For the Drug Manufacturers industry, the median Net Current Asset Value is 5.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's current Net Current Asset Value is MAD163.72, which is 2871% above median its own 10-year median of 5.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM stock overvalued right now?
Based on GuruFocus' analysis, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM (CAS:PRO) is currently considered Fairly Valued. The stock's GF Value™ is MAD1,328.12, compared to a current price of MAD1,349.00 — trading 1.6% above its estimated fair value. The current Net Current Asset Value is MAD163.72, which is 2871% above median its 10-year median of 5.51. PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM's overall GF Score™ is 84/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM (CAS:PRO), the current Net Current Asset Value is MAD163.72 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM (CAS:PRO) Overvalued in 2026?
Based on GuruFocus' analysis, PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM stock appears to be overvalued.
The current stock price of MAD1,349.00 is trading 1.6% above its estimated GF Value™ of MAD1,328.12.
GuruFocus considers PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM to be Fairly Valued.
Key valuation signals for CAS:PRO:
Net Current Asset Value: MAD163.72 (2871% above median its 10-year median of 5.51)
GF Value™: MAD1,328.12 vs. price of MAD1,349.00 (1.6% above fair value)
No single metric tells the full story. See the CAS:PRO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM Business Description
PROMOTION PHARMACEUTIQUE DU MAGHREB PROMOPHARM is engaged in production, marketing, import and export of pharmaceuticals, parapharmaceuticals, dermopharmaceuticals and cosmetics.
84GF Score
Get the complete analysis for CAS:PRO
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAS:PRO has been successfully added to your 
